Lisata Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Mazzo
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 110 Allen Road Basking Ridge NJ United States of America 07920
- IPO Date
- Mar 1, 1999
- CIK
- 0000320017
- Website
- lisata.com
- Similar Companies
- Business
- Lisata Therapeutics, Inc. Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage biopharmaceutical company that develops innovative therapies targeting advanced solid tumors and other serious diseases using its proprietary CendR Platform technology, which enables enhanced tumor-targeted and tissue-penetrating delivery of anti-cancer agents including chemotherapies, immunotherapies, and RNA-based therapeutics; the platform also selectively targets immunosuppressive cells within tumors to boost the patient's immune response. The company's lead product candidate, certepetide (formerly iRGD or CEND-1), is being evaluated in multiple ongoing clinical trials, such as the Phase 2 ASCEND study combining gemcitabine/nab-paclitaxel with certepetide or placebo for first-line metastatic pancreatic ductal adenocarcinoma in Australia and New Zealand, the Phase 2b trial of gemcitabine/nab-paclitaxel plus certepetide in China, the Phase 1 iLSTA trial adding certepetide to gemcitabine/nab-paclitaxel/durvalumab in Australia, the Phase 1 CENDIFOX trial with FOLFIRINOX plus panitumumab and certepetide for pancreatic, colon, and appendiceal cancers in the United States, the Phase 2 BOLSTER trial combining gemcitabine/cisplatin/durvalumab with certepetide or placebo for cholangiocarcinoma in the United States, and the Phase 2 trial of temozolomide with certepetide or placebo for glioblastoma multiforme in Estonia and Latvia. Founded in 1980 through predecessor entities and headquartered in Basking Ridge, New Jersey, Lisata conducts operations across the United States, Australia, New Zealand, China, and Europe, with subsidiaries including Lisata Therapeutics Australia Pty Ltd, Lisata Therapeutics Ireland Limited, Lisata Therapeutics Kabushiki Kaisha in Japan, and Lisata Therapeutics (UK) Limited. Recent developments include a strategic partnership expansion with GATC Health in June 2025 to leverage AI-driven Multiomics Advanced Technology for predicting combination therapies involving certepetide, enhancing drug discovery efficiency and derisking intellectual property; a global product license agreement with Catalent, Inc. initiated in October 2025 granting non-exclusive rights to incorporate certepetide into antibody-drug conjugates using Catalent's SMARTag technology platform, supported by positive preclinical data in November 2025 showing improved tumor penetration and efficacy; and FDA designations for certepetide including orphan drug status in pancreatic cancer since 2019 and Fast Track status since 2022.
Company News
Anthropic is compounding, OpenAI is flatlining, and the betting markets have noticed
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
Lisata Therapeutics to be acquired by Kuva Labs
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Lisata Therapeutics (LSTA) Projected to Post Quarterly Earnings on Thursday
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC Encourages PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights